IPO Databook: Silexion Therapeutics (SLXN US) - Aug 2026
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company developing proprietary RNA interference (RNAi) therapies...
100 Views
Primer: Silexion Therapeutics (SLXN US) - Aug 2026
Silexion Therapeutics is a clinical-stage biotechnology company at the forefront of developing RNA interference (RNAi) therapies for...
88 Views
Silexion Therapeutics (SLXN US): Synthetic Expert Call Transcript (10 Aug 2026)
Severe Capital Deficit: Silexion operates under extreme cash constraints, holding only $2.4 million in cash as of March 31, 2026, against a...
97 Views
No more insights